We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00483782
Recruitment Status : Completed
First Posted : June 7, 2007
Last Update Posted : August 12, 2013
Information provided by:
National Cancer Institute (NCI)

Brief Summary:

RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. It is not yet known whether giving carboplatin and paclitaxel together with bevacizumab is more effective than carboplatin and paclitaxel alone in treating patients with ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cavity cancer.

PURPOSE: This randomized phase III trial is studying carboplatin, paclitaxel, and bevacizumab to see how well they work compared with carboplatin and paclitaxel alone in treating patients with newly diagnosed ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cavity cancer.

Condition or disease Intervention/treatment Phase
Fallopian Tube Cancer Ovarian Cancer Primary Peritoneal Cavity Cancer Biological: bevacizumab Drug: carboplatin Drug: paclitaxel Other: questionnaire administration Other: study of socioeconomic and demographic variables Procedure: quality-of-life assessment Phase 3

Detailed Description:



  • Compare the progression-free survival and overall survival of patients with newly diagnosed ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer treated with carboplatin and paclitaxel with vs without bevacizumab.


  • Compare the response rate in patients treated with these regimens.
  • Compare the duration of tumor response in patients treated with these regimens.
  • Compare the biological progression-free interval, as measured by increasing CA 125 levels, in patients treated with these regimens.
  • Compare the safety (e.g., adverse events, laboratory results, and performance status) of these regimens in these patients.
  • Compare the quality of life of patients treated with these regimens.
  • Compare the cost-effectiveness of these regimens in these patients.

OUTLINE: This is a multicenter, open-label, randomized, controlled study. Patients are stratified according to FIGO stage (stage I-III with residual disease ≤ 1 cm vs stage I-III with residual disease > 1 cm vs stage IV disease), intended time to start chemotherapy after surgery (≤ 4 weeks vs > 4 weeks), and participating center. Patients are randomized to 1 of 2 treatment arms.

  • Arm I (control): Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
  • Arm II: Patients receive bevacizumab IV over 30-90 minutes followed by paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients then continue to receive bevacizumab alone every 3 weeks for 12 courses.

Quality of life is assessed at baseline, before every course, every 6 weeks for 1 year, every 3 months until disease progression or for up to 2 years, and then at 3 years. Health economic data is assessed periodically, including days of inpatient hospitalization visits, outpatient visits, and use of anticancer therapies.

After completion of study treatment, patients are followed every 3-6 months for 5 years and then annually thereafter.

Peer Reviewed and Funded or Endorsed by Cancer Research UK.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1520 participants
Allocation: Randomized
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: ICON7 - A Randomised, Two-Arm, Multi-Centre Gynaecologic Cancer InterGroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) in Patients With Epithelial Ovarian Cancer
Study Start Date : April 2006

Primary Outcome Measures :
  1. Progression-free survival

Secondary Outcome Measures :
  1. Duration of overall survival
  2. Objective response rate
  3. Duration of response
  4. Biological progression-free interval as measured by increasing CA 125 levels
  5. Safety as measured by NCI CTAE version 3.0
  6. Quality of life
  7. Health economics

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No


  • Histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer

    • Newly diagnosed disease
  • Meets 1 of the following staging criteria:

    • High-risk stage I or IIA disease (grade 3 disease or clear cell carcinoma only)
    • Stage IIB-IV disease (all grades and all histological types)
  • Must have undergone initial surgery (e.g., debulking cytoreductive surgery or a biopsy if the patient has stage IV disease) within the past 6 weeks

    • Patients with stage IV disease for which initial surgical debulking was not appropriate are eligible provided the following criteria are met:

      • Stage IV disease diagnosed by histology
      • No planned surgery prior to disease progression, including interval debulking surgery
  • Patients with prior early-stage ovarian epithelial or fallopian tube carcinoma treated with surgery alone are eligible at the time of diagnosis of abdominopelvic recurrence provided no further interval cytoreductive therapy is planned prior to disease progression
  • Synchronous primary endometrial carcinoma or a past history of primary endometrial carcinoma allowed provided the following criteria are met:

    • Disease ≤ stage IB
    • No more than superficial myometrial invasion
    • No lymphovascular invasion
    • Not poorly differentiated (i.e., no grade 3, papillary serous, or clear cell disease)
  • Measurable or nonmeasurable disease
  • No ovarian nonepithelial cancer, including malignant mixed Müllerian tumors
  • No borderline tumors (e.g., tumors of low malignant potential)
  • No history or clinical suspicion of brain metastases or spinal cord compression

    • CT scan or MRI of the brain is mandatory (within 4 weeks prior to randomization) in case of suspected brain metastases
    • Spinal MRI is mandatory (within 4 weeks prior to randomization) in case of suspected spinal cord compression


  • ECOG performance status 0-2
  • Life expectancy > 12 weeks
  • ANC ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Hemoglobin ≥ 9 g/dL (can be post-transfusion)
  • INR ≤ 1.5
  • APTT ≤ 1.5 times upper limit of normal (ULN)
  • Bilirubin ≤ 1.5 times ULN
  • ALT and AST ≤ 2.5 times ULN
  • Creatinine ≤ 2.0 mg/dL
  • Proteinuria ≤ 1+ by urine dipstick OR ≤ 1 g by 24-hour urine collection
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for ≥ 6 weeks after completion of study therapy
  • No significant traumatic injury within the past 4 weeks
  • No cerebrovascular accident, transient ischemic attack, or subarachnoid hemorrhage within the past 6 months
  • No other malignancies within the past 5 years except for adequately treated carcinoma in situ of the cervix, and/or basal cell skin cancer, and/or early endometrial carcinoma
  • No pre-existing sensory or motor neuropathy ≥ grade 2
  • No history or evidence of CNS disease (e.g., uncontrolled seizures) by neurological examination unless adequately treated with standard medical therapy
  • No history or evidence of thrombotic or hemorrhagic disorders
  • No uncontrolled hypertension (i.e., blood pressure > 150/100 mm Hg despite antihypertensive therapy)
  • No known hypersensitivity to bevacizumab and its excipients, chemotherapy, or Cremophor EL
  • No nonhealing wound, ulcer, or bone fracture

    • Patients with granulating incisions healing by secondary intention with no evidence of facial dehiscence or infection are eligible but require three weekly wound examinations
  • No clinically significant cardiovascular disease, including any of the following:

    • Myocardial infarction or unstable angina within the past 6 months
    • New York Heart Association class II-IV congestive heart failure
    • Poorly controlled cardiac arrhythmia despite medication

      • Rate-controlled atrial fibrillation allowed
    • Peripheral vascular disease ≥ grade 3 (i.e., symptomatic and interfering with activities of daily living requiring repair or revision)
  • No evidence of other disease or condition, metabolic dysfunction, physical examination findings, or laboratory findings that would contraindicate the use of an investigational drug or put the patient at high-risk for treatment-related complications


  • See Disease Characteristics
  • More than 4 weeks since other prior surgery or open biopsy
  • No prior systemic therapy for ovarian cancer (e.g., chemotherapy, monoclonal antibody therapy, tyrosine kinase inhibitor therapy, or hormonal therapy)
  • Prior adjuvant chemotherapy allowed for other malignancies (e.g., breast or colorectal carcinoma) if malignancy was diagnosed over 5 years ago with no evidence of subsequent recurrence
  • No prior mouse CA 125 antibody
  • No prior radiotherapy to the abdomen or pelvis
  • More than 10 days since prior and no concurrent chronic use of acetylsalicylic acid (> 325 mg/day)

    • Low-dose (< 325 mg/day) acetylsalicylic acid allowed
  • More than 10 days since prior and no concurrent full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes

    • Use of therapy for line patency allowed provided INR < 1.5
  • More than 30 days since prior and no other concurrent investigational agent or participation in another clinical trial
  • No other concurrent systemic antitumor agents
  • No concurrent surgery
  • No concurrent maintenance chemotherapy or intraperitoneal chemotherapy (including cytotoxic chemotherapy)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00483782

Show Show 142 study locations
Sponsors and Collaborators
Medical Research Council
Layout table for investigator information
Study Chair: Tim J. Perren, MD Leeds Cancer Centre at St. James's University Hospital
Publications of Results:
Other Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00483782    
Other Study ID Numbers: MREC-ICON7
CDR0000548777 ( Registry Identifier: PDQ (Physician Data Query) )
First Posted: June 7, 2007    Key Record Dates
Last Update Posted: August 12, 2013
Last Verified: April 2012
Keywords provided by National Cancer Institute (NCI):
stage IV ovarian epithelial cancer
Brenner tumor
ovarian carcinosarcoma
ovarian clear cell cystadenocarcinoma
ovarian endometrioid adenocarcinoma
ovarian mixed epithelial carcinoma
ovarian mucinous cystadenocarcinoma
ovarian serous cystadenocarcinoma
ovarian undifferentiated adenocarcinoma
stage IA ovarian epithelial cancer
stage IB ovarian epithelial cancer
stage IC ovarian epithelial cancer
stage IIA ovarian epithelial cancer
stage IIB ovarian epithelial cancer
stage IIC ovarian epithelial cancer
stage IIIA ovarian epithelial cancer
stage IIIB ovarian epithelial cancer
stage IIIC ovarian epithelial cancer
stage IA fallopian tube cancer
stage IB fallopian tube cancer
stage IC fallopian tube cancer
stage IIA fallopian tube cancer
stage IIB fallopian tube cancer
stage IIC fallopian tube cancer
stage IIIA fallopian tube cancer
stage IIIB fallopian tube cancer
stage IIIC fallopian tube cancer
stage IV fallopian tube cancer
stage IA primary peritoneal cavity cancer
stage IB primary peritoneal cavity cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Fallopian Tube Neoplasms
Peritoneal Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Fallopian Tube Diseases
Abdominal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Peritoneal Diseases
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action